Voya Investment Management LLC trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 2.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,531,303 shares of the biopharmaceutical company's stock after selling 72,847 shares during the quarter. Voya Investment Management LLC owned 0.12% of Bristol-Myers Squibb worth $194,911,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Brown Advisory Inc. raised its stake in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Brown Advisory Inc. now owns 256,514 shares of the biopharmaceutical company's stock valued at $18,237,000 after purchasing an additional 9,635 shares in the last quarter. Strategic Wealth Advisors Group LLC raised its stake in shares of Bristol-Myers Squibb by 9.4% in the first quarter. Strategic Wealth Advisors Group LLC now owns 34,734 shares of the biopharmaceutical company's stock valued at $2,548,000 after purchasing an additional 2,978 shares in the last quarter. Stansberry Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 4.1% in the first quarter. Stansberry Asset Management LLC now owns 203,194 shares of the biopharmaceutical company's stock valued at $14,839,000 after purchasing an additional 7,910 shares in the last quarter. American Trust acquired a new position in shares of Bristol-Myers Squibb in the first quarter valued at $368,000. Finally, Golden State Equity Partners raised its stake in shares of Bristol-Myers Squibb by 192.2% in the first quarter. Golden State Equity Partners now owns 19,611 shares of the biopharmaceutical company's stock valued at $1,432,000 after purchasing an additional 12,900 shares in the last quarter. 76.54% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of the firm's stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $69.71, for a total transaction of $1,742,750.00. Following the transaction, the chief executive officer now owns 476,104 shares in the company, valued at $33,189,209.84. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Bristol-Myers Squibb news, EVP Ann Powell sold 16,250 shares of the firm's stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $80.45, for a total transaction of $1,307,312.50. Following the transaction, the executive vice president now owns 34,226 shares in the company, valued at $2,753,481.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Giovanni Caforio sold 25,000 shares of the firm's stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $69.71, for a total value of $1,742,750.00. Following the transaction, the chief executive officer now owns 476,104 shares in the company, valued at approximately $33,189,209.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 296,111 shares of company stock worth $21,582,900. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Up 0.3 %

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings results on Wednesday, October 26th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.16. The business had revenue of $11.22 billion for the quarter, compared to analysts' expectations of $11.18 billion. Bristol-Myers Squibb had a return on equity of 50.30% and a net margin of 14.29%. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.00 earnings per share. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 7.6 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th were issued a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend was Thursday, October 6th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 70.36%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. The Goldman Sachs Group reiterated a "buy" rating and set a $85.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, September 27th. Morgan Stanley dropped their price objective on Bristol-Myers Squibb from $61.00 to $60.00 and set an "underweight" rating for the company in a research note on Thursday, October 27th. Berenberg Bank lowered Bristol-Myers Squibb from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $82.00 to $76.00 in a research note on Wednesday, September 14th. Barclays dropped their price objective on Bristol-Myers Squibb from $69.00 to $66.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 12th. Finally, Credit Suisse Group started coverage on Bristol-Myers Squibb in a research note on Thursday, November 17th. They set a "neutral" rating and a $78.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $79.00.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Read More

• Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?
• Can ZIM Defy Broad Downturn In The Container Shipping Industry?

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.